E. coli Enoyl-ACP Reductase, FABI [His] (DAG-H10047)

E. coli Enoyl-ACP Reductase, FABI [His], recombinant protein from E. coli

> 98 % as determined by SDS-PAGE
50μg; 100μg
Store it under sterile conditions at -70 °C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
E. coli is the head of the large bacterial family, Enterobacteriaceae, the enteric bacteria, which are faculatively anaerobic Gram negative rods that live in the intestinal tracts of animals in health and disease. Pili are macromolecular structures that allow binding to a digalactoside receptor in the urinary tract. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following 4 groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.
Escherichia coli; E. coli; Escherichia


Have you cited DAG-H10047 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Potential of Lichen Secondary Metabolites against Plasmodium Liver Stage Parasites with FAS-II as the Potential Target


Authors: Lauinger, Ina L.; Vivas, Livia; Perozzo, Remo; Stairiker, Christopher; Tarun, Alice; Zloh, Mire; Zhang, Xujie; Xu, Hua; Tonge, Peter J.; Franzblau, Scott G.; Duc-Hung Pham; Esguerra, Camila V.; Crawford, Alexander D.; Maes, Louis; Tasdemir, Deniz

Chemicals targeting the liver stage (LS) of the malaria parasite are useful for causal prophylaxis of malaria. In this study, four lichen metabolites, evernic acid (1); vulpic acid (2), psoromic acid (3), and, (+)-usnic acid (4), were evaluated against LS parasites of Plasmodium berghei. Inhibition Of P. falciparum blood Stage (BS) parasites was also assessed to determine stage specificity. Compound 4 displayed the highest LS activity and stage specificity (LS IC50 value 2.3 mu M, BS IC50 value 47.3 mu M). The compounds 1 - 3 inhibited one Or more enzymes (Pf FabI, PfFabG, and pfFabZ), from the Plasmodial fatty acid biosynthesis (FAS-II) pathway, a potential drug. target for LS activity. To determine species specificity and to clarify the mechanism of reported antibacterial effects, 1-4 were also evaluated against FabI homologues and Whole cells of various pathogens -(S. aureus, E. coli M. tuberculosis). Molecular modeling studies suggest that lichen acids act indirectly via binding to allosteric sites on the protein surface of the FAS-II enzymes. Potential. toxicity, of compounds was assessed in human hepatocyte and cancer cells (in vitro) as well as in a zebrafish model (in vivo):. This study indicates the therapeutic and prophylactic potential of lichen metabolites as antibacterial and antiplasmodial agents.,

Design, Synthesis and Biological Screening of Novel 1,3,4-Oxadiazoles as Antitubercular Agents


Authors: Tambe, Macchindra S.; Choudhari, Amit; Sarkar, Dhiman; Sangshetti, Jaiprakash; Patil, Rajesh; Gholap, Somnath S.

A series of novel 2,5-disubstitued 1,3,4-oxadiazole derivatives bearing 2,2-dimethyl-2,3-dihydrobenzofuran scaffold has been synthesized and screened for antitubercular activity. All the synthesized compounds were characterized by IR, H-1 NMR, C-13-NMR and Mass spectral study. The in vitro antitubercular activity of the synthesized compounds was evaluated against Mycobacterium tuberculosis H37Ra(ATCC 25177) strain. Among the synthesized compounds, four compound displayed good antitubercular activity IC50 values in low micro-gram range (<10 mu g/mL). The antitubercular data suggested that growth inhibition MTB can be imparted by the introduction of a 4- trifluoromethyl phenyl acetylene substituent. Specificity of these compounds was checked by screening them for their anti-bacterial activity against four bacterial strains (Gram-negative strains: E. coli, S. aureus; Gram-positive strains: P. aeruginosa and B. subtilis). None of the compound displayed antibacterial activity against any of the seleted strain. Molecular docking studies were carried out on InhA (FabI/ENR) which shows that the synthesized compounds bind at the catalytic site in a most favourable manner suggesting their potential as anti-mycobacterial agents. The research presented here was found to be adventitious for the development of new therapeutic agents against Mycobacterium infection.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket